Achelous Partners

Achelous Partners specializes in Mergers and Acquisitions and related corporate advisory assignments including: Sell-Side Mandates Buy-Side Mandates Valuation Modeling Fairness Opinions Mergers of public and private companies Takeover Defense Schemes of Arrangement Tender and Exchange offers Restructurings, Divestitures and Spin-offs Leveraged Buyouts and Private Equity Investments Strategic Investments and Joint Ventures

June 12, 2024 Prof. Dr. Sergi X. Trilla joins Achelous Partners as European Representative
June 12, 2024 Achelous Partners Advises Curia on its announced sale of a US CDMO site to Siegfried
April 22, 2024 Achelous Partners Advises A4P Consulting Ltd on its sale to LabConnect

June 2024

Wisconsin CDMO site is being acquired by

The undersigned acted as financial advisor to Curia Global Inc.
April 2024

has been acquired by

The undersigned acted as financial advisor to A4P Consulting
March 2024

has been acquired by

The undersigned acted as financial advisor to Six Degrees Medical
December 2023

has been acquired by

The undersigned acted as financial advisor to Bio X Cell, LLC
November 2023

has been acquired by

The undersigned acted as financial advisor to Symbio LLC
November 2023

has been acquired by

The undersigned acted as financial advisor to Proinnovera, GmbH
November 2023

has been acquired by

The undersigned acted as financial advisor to Pharmalog, GmbH
January 2023

has been acquired by

The undersigned acted as financial advisor to ECIR Medical Communications Inc.
January 2023

has been acquired by

The undersigned acted as financial advisor to Alcedis, GmbH
November 2022

has been acquired by

The undersigned acted as financial advisor to Expression Systems, LLC
October 2022

has been acquired by

The undersigned acted as financial advisor to AQW Holdings, Inc. d.b.a. Qfix
August 2022

has been acquired by

The undersigned acted as financial advisor to AusDiagnostics
July 2022

has been acquired by

The undersigned acted as financial advisor to Cergentis B.V.
July 2022

has been acquired by

The undersigned acted as financial advisor to proderm GmbH
June 2022

has been acquired by

The undersigned acted as financial advisor to SAI MedPartners
February 2022

has acquired

The undersigned acted as financial advisor to TCP Analytical
November 2021

has been acquired by

The undersigned acted as financial advisor to Regulatory Compliance Associates Inc.
August 2021

has been acquired by

The undersigned acted as financial advisor to DRG International Inc.
August 2021

has been acquired by

The undersigned acted as financial advisor to bioskin GmbH
July 2021

has been acquired by

The undersigned acted as financial advisor to nanoComposix Holdings, Inc.
May 2021

has been acquired by

The undersigned acted as financial advisor to Clinical Outcomes Solutions
March 2021

has been acquired by

The undersigned acted as financial advisor to Diamond Pharma Services
February 2021

has been acquired by

The undersigned acted as financial advisor to Delphi Genetics
October 2020

has been acquired by

The undersigned acted as financial advisor to MD Biosciences, Inc.
September 2020

has been acquired by

The undersigned acted as financial advisor to American Laboratory Products Company, Ltd.
September 2020

has been acquired by

The undersigned acted as financial advisor to Maetrics LLC
August 2020

has been acquired by

The undersigned acted as financial advisor to CTK Biotech, Inc.
February 2020

has been acquired by

The undersigned acted as financial advisor to BresMed Health Solutions Ltd
January 2020

has been acquired by

The undersigned acted as financial advisor to Statistics Collaborative, Inc.
December 2019

has been acquired by

The undersigned acted as financial advisor to MLM Medical Labs GmbH
October 2019

has been acquired by

The undersigned acted as financial advisor to Specialized Medical Services-oncology BV
July 2019

has been acquired by

The undersigned acted as financial advisor to Eurolyser Diagnostica GmbH
July 2019

has acquired

The undersigned acted as financial advisor to LifeSpan BioSciences
March 2019

has been acquired by

The undersigned acted as financial advisor to Quorum Review, Inc.
January 2019

has been acquired by

The undersigned acted as financial advisor to ProductLife Group
January 2019

has been acquired by

The undersigned acted as financial advisor to CoreBiome, Inc.
October 2018

has been acquired by

The undersigned acted as financial advisor to Pennside Partners Ltd.
September 2018

has been acquired by

The undersigned acted as financial advisor to NovaTec Immundiagnostica GmbH
September 2018

has acquired

The undersigned acted as financial advisor to Thompson Street Capital Partners
September 2018

has been acquired by

The undersigned served as financial advisor to HyTest Ltd.
July 2018

has been acquired by

The undersigned served as financial advisor to Gold Standard Diagnostics Corp.
May 2018

has been acquired by

The undersigned served as financial advisor to Biovian Oy
January 2018

has been acquired by

The undersigned served as financial advisor to LifeCodexx AG
June 2017

has been acquired by

The undersigned acted as financial advisor to Coté Orphan, LLC
May 2017

has been acquired by

The undersigned acted as financial advisor to PharmaCell B.V.
April 2017

has been acquired by

The undersigned acted as financial advisor to Emergo Group, Inc.
April 2017

has been acquired by

The undersigned acted as financial advisor to Calbiotech, Inc.
January 2017

has been acquired by

The undersigned acted as financial advisor to BioControl Systems, Inc.
August 2016

has been acquired by

The undersigned acted as financial advisor to SPEware Corporation
July 2016

has acquired

The undersigned acted as financial advisor to Sharps Compliance Corp.
June 2016

has been acquired by

The undersigned acted as financial advisor to Cisbio Bioassays
December 2015

has acquired

The undersigned acted as financial advisor to Abzena plc
December 2015

has acquired

The undersigned acted as financial adviser to Sharps Compliance Corp.
October 2015

has been acquired by

The undersigned acted as financial advisor to Kinesis Pharma BV
August 2015

has been acquired by

The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
July 2015

has acquired

The undersigned acted as financial advisor to Sharps Compliance Corp.
March 2015

has acquired

The undersigned acted as financial advisor to Ansell Limited
July 2014

has been acquired by

The undersigned acted as financial advisor to IBL International Holding BV
July 2014

has been acquired by

The undersigned served as financial advisor to Phlexglobal Limited
June 2014

has been acquired by

The undersigned served as financial advisors to Pharmalink Consulting
December 2013

has acquired assets from

The undersigned acted as advisor to Valeant Pharmaceuticals International
August 2013

has been acquired by

The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
July 2013

has been acquired by

The undersigned acted as financial advisor to The Anson Group LLC
July 2013

has signed a definitive agreement to sell its orthopedic implant assets and business to

an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
July 2013

has been acquired by

The undersigned acted as financial advisor to Kreatech Holding B.V.
July 2013

has been acquired by

USD$10,000,000

The undersigned acted as financial advisor to Matrical Bioscience Inc
May 2013

has been acquired by

The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
August 2012

has been acquired by

The undersigned acted as advisor to JSW Life Sciences GmbH
March 2012

has acquired assets from

US$164M plus up to US$20M in milestones

The undersigned acted as advisor to Valeant Pharmaceuticals International
December 2011

invests in

The undersigned acted as advisor to Ansell Limited for the investment
August 2010

has been acquired by

The undersigned acted as financial advisor to EnviroLogix, Inc.
March 2010

has been acquired by

USD$59,000,000

The undersigned acted as financial advisor to Finnzymes Oy
December 2009

has licensed its ReGet® drug delivery system for ophthalmic indications to

The undersigned acted as financial advisor to BTG olc
October 2009

has been acquired by

The undersigned acted as financial advisor to Anaspec Inc.
August 2009

has sold its HySolv™ drug delivery technology to

The undersigned acted as financial advisor to BTG plc
January 2009

has been acquired by

The undersigned acted as financial advisor to the shareholders of Labcoat Limited
December 2008

has acquired

The undersigned is acting as financial advisor to Biocompatibles International
December 2008

has acquired

The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
February 2008

has been acquired by

The undersigned is acting as financial advisor to Sigma Pharmaceuticals
January 2008

has been acquired by

The undersigned is acting as financial advisor to Panbio Limited
May 2007

has acquired

The undersigned acted as financial advisor to Ansell Limited
March 2007

has sold its Human Health point-of-care diagnostic products business to

The undersigned acted as financial advisor to Agenix Limited
February 2007

Strategic alliance and investment of up to £32,100,000 in

The undersigned acted as financial advisor to GeneMedix, PLC
December 2006

Announced M&A advisory and restructuring

The undersigned acted as financial advisor to Panbio Limited
December 2006

has acquired

The undersigned acted financial advisor to Novozymes A/S
August 2006

has acquired

The undersigned acted as financial advisor to Meditech Research Limited
July 2006

has acquired Delta Biotechnology Ltd from

The undersigned acted as financial advisor to Novozymes A/S
April 2006

has assigned IP and granted distribution rights for its Animal Health business to

The undersigned acted as financial advisor to Agenix Limited
October 2005

M&A advisory and valuation analysis

The undersigned acted as financial advisor to CogState Limited
September 2005

NASDAQ listing of ADRs (American Depositary Receipts)

The undersigned acted as advisor to Genetic Technologies Limited
June 2005

NASDAQ listing of ADRs (American Depositary Receipts)

The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
January 2005

awarded to

for its investment banking role in the creation of
December 2004

has been acquired by

The undersigned acted as financial advisor to AGT Biosciences Ltd.

Our Competence	Our bankers provide high quality senior-level advice and expertise to the Boards of our corporate clients We specialize in the healthcare, life science, biotech and pharma industry sectors, allowing us to provide insight and shape a strategy that is most relevant to those sectors We have the right combination of diverse backgrounds in investment banking, capital markets, legal, life science industry and academia, to be able to manage the most complex cross-border transactions We fulfill our clients’ desire for objective independent advice We assist our clients to originate and execute assignments, no matter how complex We transact across the entire spectrum of deal size
Our Independence	Not only are we independent but we are perceived to be independent We are specialist corporate advisors free to operate without the pressure to cross-sell other products and services We are not partial to the size of deals, our only incentive is to push for the best deal in order for us to earn our client's trust on the next assignment
Our Difference	Our bankers spend significant time meeting clients and potential M&A opportunities across North America, Europe, Australia, Asia and Latin America We service clients globally with our own office in New York and through relentless traveling We bring a global perspective combined with local knowledge and technical expertise We provide a broader choice of targets and acquirors We have significant expertise in structuring cross-border deals which provide value added outcomes for our clients’ shareholders We advise a broad range of small, medium and large public and private enterprises around the globe
How We Work	Our bankers spend significant time and energy getting to know our clients’ businesses and understanding their strategic objectives We are results/solutions driven We provide and maintain absolute client confidentiality We provide the highest quality independent advice to our clients’ Boards We are acutely aware of the importance of management and cultural fit We focus on efficient deal execution We strive to create shareholder value for our clients